Roche Holding plans to stop developing ocrelizumab as a treatment for rheumatoid arthritis because the drug's risk profile proved to be unfavorable when compared with existing treatments in an effectiveness and safety review. Roche said midstage trials of the drug, co-developed by Biogen Idec, for relapsing remitting multiple sclerosis are ongoing.

Related Summaries